Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Sells $106,599.15 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach sold 33,841 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now owns 7,029,674 shares of the company’s stock, valued at approximately $22,143,473.10. This represents a 0.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Puma Biotechnology Price Performance

NASDAQ PBYI opened at $2.95 on Friday. The stock’s fifty day moving average price is $2.99 and its 200 day moving average price is $2.97. Puma Biotechnology, Inc. has a 1 year low of $2.22 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The company has a market cap of $144.81 million, a price-to-earnings ratio of 6.15 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.10. The firm had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same period last year, the business posted $0.12 earnings per share. As a group, equities research analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analyst Ratings Changes

PBYI has been the subject of a number of research analyst reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research note on Monday, December 23rd.

Institutional Trading of Puma Biotechnology

Several large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its holdings in Puma Biotechnology by 63.6% in the second quarter. Bank of New York Mellon Corp now owns 308,997 shares of the biopharmaceutical company’s stock valued at $1,007,000 after purchasing an additional 120,104 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Puma Biotechnology by 2,309.9% in the 2nd quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 48,184 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Puma Biotechnology in the second quarter worth about $54,000. Rice Hall James & Associates LLC grew its holdings in Puma Biotechnology by 3.3% during the second quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock worth $472,000 after acquiring an additional 4,686 shares during the period. Finally, American Century Companies Inc. raised its position in Puma Biotechnology by 98.5% during the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares in the last quarter. 61.29% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.